Anti-PDL1 antibodies, activatable anti-PDL1 antibodies, and methods of use thereof

US10669339B2 · kind B2 · utility

Assignee

• CytomX Therapeutics, Inc. · US

Inventors

• James William West · Lompoc, US
• Li Mei · San Francisco, US
• Stephen Moore · Las Vegas, US
• Margaret Thy Luu Nguyen · San Francisco, US
• Daniel Robert Hostetter · Palo Alto, US
• Olga Vasiljeva · Cupertino, US
• Jason Gary Sagert · Lompoc, US
• Jonathan Alexander Terrett · Slough, GB

Key dates

• Filing date: May 31, 2019
• Grant date: Jun 2, 2020
• Expiry date: May 31, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/92
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates generally to antibodies that bind programmed death ligand 1 (PDL1), activatable antibodies that specifically bind to PDL1 and methods of making and using these anti-PDL1 antibodies and anti-PDL1 activatable antibodies in a variety of therapeutic, diagnostic and prophylactic indications.